DRI Healthcare Trust

DHT.U

CA23344H1091

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 21:00:00 27/06/2024 BST			5-day change	1st Jan Change
15.38 ^CAD	-0.90%		-0.84%	+23.24%

05-07	Transcript : DRI Healthcare Trust, Q1 2024 Earnings Call, May 07, 2024
05-06	DRI Healthcare Trust Brief: Q1 Total Income of US$42.1 million; Comprehensive Loss of US$5.0 million; Adjusted Cash Earnings per Unit of US$0.47 (basic and diluted); Net Loss per Unit of US$0.11 (basic and diluted)	MT

DRI Healthcare Trust Announces Impairment Charges for the First Quarter Ended March 31, 2024

May 06, 2024 at 10:03 pm

DRI Healthcare Trust announced Impairment charges for the first quarter ended March 31, 2024. For the period, the company reported Impairment of royalty assets of USD 4,451,000.

Latest news about DRI Healthcare Trust

Transcript : DRI Healthcare Trust, Q1 2024 Earnings Call, May 07, 2024	05-07
DRI Healthcare Trust Brief: Q1 Total Income of US$42.1 million; Comprehensive Loss of US$5.0 million; Adjusted Cash Earnings per Unit of US$0.47 (basic and diluted); Net Loss per Unit of US$0.11 (basic and diluted)	05-06	MT
DRI Healthcare Trust Announces Impairment Charges for the First Quarter Ended March 31, 2024	05-06	CI
Dri Healthcare Trust Declares Quarterly Cash Distribution for the Second Quarter of 2024, Payable on July 19, 2024	05-06	CI
DRI Healthcare Trust Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
DRI Healthcare Trust Brief: Adds Transaction "Significantly" Reduces Potential Dilution With a Net Reduction of Warrants Equivalent to 8.2% of Units Outstanding	04-23	MT
DRI Healthcare Trust Brief: Says Closed Prior Announced Refinancing of Preferred Securities	04-23	MT
DRI Healthcare Trust Refinances Preferred Securities	04-15	MT
DRI Healthcare Trust Seeks Acquisitions	02-29	CI
Transcript : DRI Healthcare Trust, Q4 2023 Earnings Call, Feb 29, 2024	02-29
DRI Healthcare Trust Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
DRI Healthcare Trust Declares Quarterly Cash Distribution for the First Quarter of 2024, Payable on April 19, 2024	02-28	CI
DRI Healthcare Trust Brief: Announcing 2024 royalty income guidance of US$153 to US$155 million, excluding milestone income and any new transactions	02-28	MT
DRI Healthcare Trust Brief: Q4 Net Earnings per Unit of US$0.39 (basic and diluted; Increasing quarterly cash distribution	02-28	MT
DRI Healthcare Trust Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Tranche Update on DRI Healthcare Trust (TSX:DHT.UN)'s Equity Buyback Plan announced on November 13, 2023.	02-28	CI
National Bank Raises DRI Healthcare Target to $22 on Omidria News, Guidance Increase	02-01	MT
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance	02-01	MT
DRI Healthcare Trust Brief: Announcing Expansion of its Royalty Entitlement on the US Net Sales of Omidria), Updating Deployment and CAGR Guidance	02-01	MT
National Bank Highlights Key Takeaways From DRI Healthcare Trust's Investor Meetings; Raises Price Target	12-22	MT
DRI Healthcare Trust Brief: Says This special cash distribution is in addition to quarterly cash distribution declared on November 13, 2023 of US$0.075 per trust unit	12-20	MT
DRI Healthcare Trust Brief: Special cash distribution will be made payable to unitholders of record at close of business on December 31, 2023, and paid to such unitholders on January 19, 2024	12-20	MT
DRI Healthcare Trust Brief: Declaring a special cash distribution in the amount of US$0.2662 per trust unit	12-20	MT
DRI Healthcare Trust Declares Special Distribution, Payable on January 19, 2024	12-20	CI
Transcript : DRI Healthcare Trust, Q3 2023 Earnings Call, Nov 14, 2023	11-14

DRI Healthcare Trust is a Canada-based company, which is engaged in providing financing to advance innovation in the life sciences industry. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It is acquiring approximately 70 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara. The Companyâs portfolio includes Empaveli, Eylea, Natpara, Omidria, Rydapt, Simponi, Syfovre, Vonjo, Zejula and Zytiga. Its therapeutic areas include influenza, endocrinology, ophthalmology, dermatology, oncology, neurology, autoimmune diseases, heme-onc, lysosomal storage disorder, respiratory diseases, oncology and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; Novartis; Biogen; CTI Biopharma; Roche, Novartis, Johnson & Johnson, and others.

Sector

Pharmaceuticals

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for DRI Healthcare Trust

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.33 USD

Average target price

14.94 USD

Spread / Average Target

+31.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DRI HEALTHCARE TRUST	+23.24%	636M
ELI LILLY AND COMPANY	+55.95%	811B
NOVO NORDISK A/S	+43.62%	640B
JOHNSON & JOHNSON	-6.98%	353B
MERCK & CO., INC.	+19.08%	333B
ABBVIE INC.	+9.05%	302B
ASTRAZENECA PLC	+16.30%	246B
ROCHE HOLDING AG	+2.41%	225B
NOVARTIS AG	+12.47%	218B
AMGEN INC.	+8.91%	168B

Other Pharmaceuticals